Avalyn Pharma Inc. (AVLN)
| Market Cap | 1.54B |
| Revenue (ttm) | n/a |
| Net Income | -103.31M |
| EPS | -12.34 |
| Shares Out | 44.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 202,893 |
| Open | 36.45 |
| Previous Close | 36.51 |
| Day's Range | 34.37 - 36.45 |
| 52-Week Range | 24.15 - 40.17 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 62.25 (+79.45%) |
| Earnings Date | Aug 12, 2026 |
About AVLN
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for AVLN stock is "Strong Buy." The 12-month stock price target is $62.25, which is an increase of 79.45% from the latest price.
News
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations describe integration of patient perspective into cli...
Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Avalyn Pharma (AVLN) to $57 from $53 and keeps an Overweight rating on the shares.
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Socie...
Avalyn Pharma Quarterly report: Q2 2026
Avalyn Pharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
Avalyn Pharma Earnings release: Q2 2026
Avalyn Pharma released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Avalyn Pharma completes target enrollment in MIST trial
Avalyn Pharma (AVLN) announced that it has completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 in patients with progressive pulmonary fibrosis. Additional patients…
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027
Avalyn Pharma Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing inhaled therapies for pulmonary fibrosis, aiming to improve tolerability and efficacy over current oral treatments. Key programs are in late-stage clinical trials, with strong long-term data and a robust financial position to support further development and potential market leadership.
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favor...
Avalyn Pharma Earnings release: Q1 2026
Avalyn Pharma released its Q1 2026 earnings on June 3, 2026, summarizing the period's financial results.
Avalyn Pharma Quarterly report: Q1 2026
Avalyn Pharma has published its Q1 2026 quarterly earnings report on June 3, 2026.
Avalyn to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare...
Avalyn Pharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner initiated coverage of Avalyn Pharma (AVLN) with an Outperform rating and $51 price target Avalyn has “a strong respiratory pipeline” and the characteristics to...
Avalyn Pharma initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Avalyn Pharma (AVLN) with an Overweight rating and $53 price target The company is well positioned to address the “pressing unmet needs” of pulmonary fibrosis…
Avalyn Pharma initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $80 price target The firm has “high conviction” in the “multi-blockbuster sales” potential for Aval...
Avalyn Pharma initiated with a Buy at Jefferies
Jefferies initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $52 price target The firm says the company is “solving right problem in pulmonary fibrosis by delivering proven…
Avalyn Pharma initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $80 price target
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare...
Avalyn Pharma Slides: Corporate presentation
Avalyn Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare...
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare...
Avalyn Pharma indicated to open at $25.25, IPO priced at $18.00
12:03 EDT Avalyn Pharma (AVLN) indicated to open at $25.25, IPO priced at $18.00
Avalyn Pharma opens at $26.00, IPO priced at $18.00
Avalyn Pharma (AVLN) priced 16.67M shares at $18.00. The deal priced at the top end of its $16.00-$18.00 target range. Morgan Stanley, Jefferies, Evercore ISI and Guggenheim are acting as…
Avalyn Pharma 16.67M share IPO priced at $18.00
The deal priced at the top end of its $16.00-$18.00 target range. Morgan Stanley, Jefferies, Evercore ISI and Guggenheim are acting as joint book running managers for the offering. Published…
Avalyn Announces Pricing of Upsized Initial Public Offering
BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of ...